GTBP faces a high probability of delisting by November 16, 2026, unless the stock price recovers above $1 for 10 consecutive business days. The company has no disclosed reverse-split or capital-raise plan. Traders should expect continued downward pressure and potential OTC transfer. Monitor for any reverse-split announcement or capital infusion as the only realistic path to compliance.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 22 $0.4400entry
- T+1 · 6mo ago −10.91%α −11.49% · $0.3920
- T+5 · 6mo ago +0.45%α −1.22% · $0.4420
- T+20 · 5mo ago +13.64%α +15.05% · $0.5000
- T+60 · 3mo ago −37.41%α −40.60% · $0.2754
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
GT Biopharma received a Nasdaq notice granting an additional 180-day compliance period until November 16, 2026, to regain the $1.00 minimum bid price requirement. The stock has been below $1 since at least November 2025, and the company previously restated financials in March 2026 due to a liability classification error. Delisting risk remains elevated if the bid price does not recover.
Key Facts
- Nasdaq granted an additional 180-day compliance period until November 16, 2026, to meet the $1.00 minimum bid price rule.
- The initial 180-day compliance period (from November 20, 2025) expired on May 19, 2026, without compliance being achieved.
- The company previously restated its Q2 and Q3 2025 financials on March 1, 2026, due to a $28.7M liability classification error on Greenshoe Rights.
- Market cap is approximately $16M, and the stock has been trading below $1 for over six months.
- The company stated it will monitor the bid price and assess options, but gave no specific plan to regain compliance.
Financial Impact
No specific financial impact quantified in the filing. The delisting risk alone threatens Nasdaq listing, which typically reduces institutional ownership and liquidity.
Risk Factors
- Failure to regain $1 bid price by November 16, 2026, will result in Nasdaq delisting and transfer to OTC markets.
- The March 2026 restatement signals accounting control weaknesses, which may complicate any capital raise or reverse-split approval.
- No specific compliance plan has been disclosed, increasing uncertainty around the timeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-024913 |
| Document: 0001493152-26-024913-index-headers.html | 0001493152-26-024913 |
| Document: 0001493152-26-024913-index.html | 0001493152-26-024913 |
| Document: 0001493152-26-024913.txt | 0001493152-26-024913 |
Track record
12 reports on GTBP
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today Press Release Neutral 3/10 Entry $3.72 Now $3.54 −4.97% settles Feb 12
- Oct 21, 202627d ago EFFECT Bearish 6/10 Entry $5.41 Now $3.54 +34.66% settles Jan 19
- Oct 13, 20264w ago DEF 14A Bearish 7/10 Entry $6.21 Now $3.54 +43.08% settles Jan 11
- Oct 9, 20265w ago S-1 Bearish 7/10 Entry $6.80 Now $3.54 +48.01% settles Jan 7
- Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.80 Now $3.54 −48.01% settles Dec 22
- Sep 15, 20268w ago 8-K Bearish 7/10 Entry $9.00 Now $3.54 +60.72% settles Dec 9
- Sep 3, 202610w ago 8-K Neutral 4/10 Entry $0.2524 Now $3.54 +1300.55% settles Nov 30
- Aug 14, 202613w ago Press Release Bearish 5/10 Entry $0.2960 to $0.1728 Now $3.54 −1094.26% ▲ +41.62% +38.58% vs SPY
- May 22, 202625w ago 8-K Bearish 7/10 Viewing Entry $0.4400 to $0.2754 Now $3.54 −703.41% ▲ +37.41% +40.60% vs SPY
- Apr 30, 202628w ago S-1 Bearish 7/10 Entry $0.3430 to $0.3167 Now $3.54 −930.61% ▲ +7.67% +10.74% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers